Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol. 2009;27:911–918.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Richards SM, Chopra M, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL XII/ECOG 2993 study. Blood. 2007;109:944–950.
   PubMed Web of Science ®Google Scholar
• Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21:1907–1914.
   PubMed Web of Science ®Google Scholar
• Gokbuguet N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120:2032–2041.
   PubMed Web of Science ®Google Scholar
• Groupe Français de Cytogénétique Hématologique. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. Blood. 1996;87:3135–3142.
   PubMed Web of Science ®Google Scholar
• Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960;25:85–109.
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293.
   PubMed Web of Science ®Google Scholar
• Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277–280.
   PubMed Web of Science ®Google Scholar
• Prywes R, Foulkes JG, Baltimore D. The minimum transforming region of v-abl is the segment encoding protein-tyrosine kinase. J Virol. 1985;54:114–122.
   PubMed Web of Science ®Google Scholar
• Maino E, Sancetta R, Viero P, et al. Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther. 2014;14:723–740.
   PubMed Web of Science ®Google Scholar
• Ravandi F. Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation. Hematology Am Soc Hematol Educ Program. 2017;2017:22–27.
   PubMed Web of Science ®Google Scholar
• Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinibGRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood Marrow Transplant. 2013;19:150–155.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123:843–850.
   PubMed Web of Science ®Google Scholar
• Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015;125:3711–3719.
   PubMed Web of Science ®Google Scholar
• Lee KH, Lee JH, Choi SJ, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2005;19:1509–1516.
   PubMed Web of Science ®Google Scholar
• Yanada M, Takeuchi J, Sugiura J, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460–466.
   PubMed Web of Science ®Google Scholar
• Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644–3652.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Garcia O, Montesinos P, et al. Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation. Br J Haematol. 2012;159:78–81.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Garcia O, Oriol A, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016;41:12–20.
   PubMed Web of Science ®Google Scholar
• Daver N, Thomas D, Ravandi F, et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica. 2015;100:653–661.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469–1477.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Othus M, O’Brien SM, et al. US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome-positive ALL. Blood Adv. 2016;1:250–259.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Coude MM, Gökbuget N, et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL. Blood. 2016;128(6):774–782.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Pfeifer H, Cayuela JM, et al. Nilotinib (Tasigna) and chemotherapy BCR-ABL1 positive acute lymphoblastic leukemia (ALL): a trial of the European working group for adult ALL (EWALL-PH-02). Blood. 2014;124:798.
   Web of Science ®Google Scholar
• Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015;126:746–756.
   PubMed Web of Science ®Google Scholar
• Slayton WB, Schultz KR, Kairalla JA, et al. Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: results of children’s oncology group trial AALL0622. J Clin Oncol. 2018;36:2306–2314.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Kantarjian HM, Kim DW, et al. Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors. Am J Hematol. 2015;90:755–768.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-center, phase 2 study. Lancet Oncol. 2015;16:1547–1555.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Piciocchi A, Papayannidis C, et al. First report of the GIMEMA LAL1811 phase II prospective study of the combination of steroids with ponatinib as frontline therapy of elderly or unfit patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2017;130:99.
   Web of Science ®Google Scholar
• Houot R, Tavernier E, Le QH, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia in the elderly: prognostic factors and treatment outcome. Hematology. 2004;9:369–376.
   PubMedGoogle Scholar
• Byun JM, Koh Y, Shin DY, et al. BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. Haematologica. 2017;102:e187–e190.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109:3676–3678.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Vitale A, Vignetti M, et al. A sequential approach with imatinib, chemotherapy and transplant and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study. Haematologica. 2016;101:1544–1552.
   PubMed Web of Science ®Google Scholar
• Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521–6528.
   PubMed Web of Science ®Google Scholar
• Chiaretti S, Vitale A, Elia L, et al. Multicenter total therapy GIMEMA LAL 1509 protocol for de novo adult Ph+ acute lymphoblastic leukemia (ALL) patients. Updated results and refined genetic-based prognostic stratification. Blood. 2015;126:81.
   Web of Science ®Google Scholar
• Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504–507.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–4164.
   PubMed Web of Science ®Google Scholar
• Brissot E, Labopin M, Beckers MM, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2015;100:392–399.
   PubMed Web of Science ®Google Scholar
• Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99:111–115.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122:1214–1221.
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3:e170580.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kantarjian HM, Brüggemann M, et al. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2019;3:3033–3037.
   PubMed Web of Science ®Google Scholar
• Brüggemann M, Kotrova M. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv. 2017;1:2456–2466.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Short NJ, Jorgensen JL, et al. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2017;123:294–302.
   PubMed Web of Science ®Google Scholar
• Spinelli O, Peruta B, Tosi M, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612–618.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Kneba M, Raff T, et al. German multicenter study for adult acute lymphoblastic leukemia. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–1876.
   PubMed Web of Science ®Google Scholar
• Van Dongen JJ, van der Velden VH, Bruggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996–4009.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Cazzaniga G, van der Velden VHJ, et al. Standardization and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. 2019;33:1910–1922.
   PubMed Web of Science ®Google Scholar
• Lussana F, Intermesoli T, Gianni F, et al. Achieving molecular remission before allogeneic stem cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact on relapse and long-term outcome. Biol Blood Marrow Transplant. 2016;22:1983–1987.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Imai K, Mizuta S, et al. Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016;51:43–50.
   PubMed Web of Science ®Google Scholar
• Scheuring UJ, Pfeifer H, Wassmann B, et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) during imatinib treatment. Leukemia. 2003;17:1700–1706.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013;27:1254–1262.
   PubMed Web of Science ®Google Scholar
• Clappier E, Kim R, Cayuela JM. et al. Persistent BCR-ABL1 clonal hematopoiesis after blast clearance identifies a CML-like subgroup of patients with Philadelphia chromosome-positive (Ph+) ALL: interim results from the GRAAPH-2014 trial. Eur Hematol Assoc. 2018;abstract S1568.
   Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727–734.
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120:1002–1009.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Garcia O, Moreno MJ, et al. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA group. Cancer. 2019;125:2810–2817.
   PubMed Web of Science ®Google Scholar
• Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26:428–442.
   PubMed Web of Science ®Google Scholar
• Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study group. Haematologica. 2010;95:589–596.
   PubMed Web of Science ®Google Scholar
• Spyridonidis A, Labopin M, Schmid C, et al. Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia. 2012;26:1211–1217.
   PubMed Web of Science ®Google Scholar
• Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: results from a phase 3 study. Am J Hematol. 2010;85:164–170.
   PubMed Web of Science ®Google Scholar
• Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014;89:282–287.
   PubMed Web of Science ®Google Scholar
• AbouDalle I, Kantarjian HM, Short NJ, et al. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol. 2019;94:1388–1395.
   PubMed Web of Science ®Google Scholar
• Rea D, Legros L, Raffoux E, et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006;20:400–403.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16:401–412.
   PubMed Web of Science ®Google Scholar
• Gibbons DL, Pricl S, Posocco P, et al. Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci USA. 2014;111:3550–3555.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–2088.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404.
   PubMed Web of Science ®Google Scholar
• Tavitian S, Uzunov M, Bérard E, et al. Ponatinib-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the real-life OPAL study. Leuk Lymphoma. 2020. [Online ahead of print]. DOI:10.1080/10428194.2020.1762876
   Web of Science ®Google Scholar
• Dorer DJ, Knickerbocker RK, Baccarani M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91.
   PubMed Web of Science ®Google Scholar
• Abid MB, De Mel S. Does ponatinib cross the blood-brain barrier? Br J Haematol. 2017;179:497–498.
   PubMed Web of Science ®Google Scholar
• Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017;543:733–737.
   PubMed Web of Science ®Google Scholar
• Schoepfer J, Jahnke W, Berellini G, et al. Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1. J Med Chem. 2018;61:8120–8135.
   PubMed Web of Science ®Google Scholar
• Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019;36:431–443.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Hofmann WK, et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res. 2003;9:4674–4681.
   PubMed Web of Science ®Google Scholar
• Takayama N, Sato N, O’Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol. 2002;119:106–108.
   PubMed Web of Science ®Google Scholar
• Alimena G, Breccia M, Latagliata R, et al. Dasatinib in the management of lymphoid blast crisis of Philadelphia-positive chronic myeloid leukemia with multiple extra-medullary and intracranial localization. Leuk Res. 2009;33:e134–e136.
   PubMedGoogle Scholar
• Abdelhalim A, Barcos M, Block AW, et al. Remission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy. Leuk Lymphoma. 2007;48:1053–1056.
   PubMed Web of Science ®Google Scholar
• Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008;112:1005–1012.
   PubMed Web of Science ®Google Scholar
• Slevin ML, Piall EM, Aherne GW, et al. The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy. Med Pediatr Oncol. 1982;10(suppl.1):157–168.
   PubMedGoogle Scholar
• Warraich Z, Tenneti P, Thai T, et al. Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for Philadelphia chromosome-positive acute lymphoblast leukemia: a systematic review. Biol Blood Marrow Transplant. 2020;26:e55–e64.
   PubMedGoogle Scholar
• Katz BZ, Herishanu Y. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond. Leuk Lymphoma. 2014;55:999–1006.
   PubMed Web of Science ®Google Scholar
• Del Nagro CJ, Otero DC, Anzelon AN, et al. CD19 function in central and peripheral B-cell development. Immunol Res. 2005;31:119–131.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;136:334–342.
   PubMed Web of Science ®Google Scholar
• Klinger M, Brandl C, Zugmaier G, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood. 2012;119:6226–6233.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicenter, single-arm, phase 2 study. Lancet Oncol. 2015;16:57–66.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Boissel N, Chevallier P, et al. Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol. 2017;35:1795–1802.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Ribera JM, Kantarjian HM, et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 2020;126:304–310.
   PubMed Web of Science ®Google Scholar
• Assi R, Kantarjian H, Short NJ, et al. Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk. 2017;17:897–901.
   PubMed Web of Science ®Google Scholar
• Sokolov A, Parovichnikova E, Short N, et al. Blinatumomab + tyrosine kinase inhibitors with no chemotherapy in BCR-ABL-positive or IKZF1-deleted or FLT3-ITD-positive relapsed/refractory acute lymphoblastic leukemia patients: high molecular remission rate and toxicity profile. Blood. 2017;130:3884.
   Web of Science ®Google Scholar
• King AC, Pappacena JJ, Tallman MS, et al. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Res. 2019;79:27–33.
   PubMed Web of Science ®Google Scholar
• Couturier MA, Thomas X, Raffoux E, et al. Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Blood. 2018;132:4014.
   Web of Science ®Google Scholar
• El Chaer F, Holtzman NG, Sausville EA, et al. Relapsed Philadelphia chromosome-positive Pre-B-ALL after CD19-directed CAR-T cell therapy successfully treated with combination of blinatumomab and ponatinib. Acta Haematol. 2019;141:107–110.
   PubMed Web of Science ®Google Scholar
• Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology. 2016;2016:567–572.
   PubMed Web of Science ®Google Scholar
• Stein AS, Schiller G, Benjamin R, et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann Hematol. 2019;98:159–167.
   PubMed Web of Science ®Google Scholar
• Braig F, Brandt A, Goebeler M, et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood. 2017;129:100–104.
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Callahan MK, Postow MA, et al. On being less tolerant: enhanced cancer immonosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med. 2015;7:280sr1.
   PubMed Web of Science ®Google Scholar
• Duell J, Dittrich M, Bedke T, et al. Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 2017;31:2181–2190.
   PubMed Web of Science ®Google Scholar
• Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522–1531.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012;120:5185–5187.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Arpinati M, Candoni A, et al. Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2011;52:325–327.
   PubMed Web of Science ®Google Scholar
• Zein N, Sinha AM, McGahren WJ, et al. Calicheamicin gamma 1l: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science. 1988;240:1198–1201.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calicheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13:403–411.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119:2728–2736.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375:740–753.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019;125:2474–2487.
   PubMed Web of Science ®Google Scholar
• Jain N, Cortes JE, Ravandi F, et al. Inotuzumab ozogamicin in combination with bosutinib for patients with relapsed or refractory Ph+ ALL or CML in lymphoid blast phase. Blood. 2017;130:143.
   Web of Science ®Google Scholar
• Marks DI, Kebriaei P, Stelljes M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019;25:1720–1729.
   PubMed Web of Science ®Google Scholar
• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024–10028.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–528.
   PubMed Web of Science ®Google Scholar
• Gardner RA, Finney O, Annesley C, et al. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. Blood. 2017;129:3322–3331.
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–2138.
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459.
   PubMed Web of Science ®Google Scholar
• Saito S, Nakazawa Y, Sueki A, et al. Anti-leukemic potency of piggyback-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Cytotherapy. 2014;16:1257–1269.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang M, Ramos C, et al. Closely-related T-memory stem cells correlate with in-vivo expansion of CAR.CD19-T cells in patients and are preserved by IL-7 and IL-15. Blood. 2014;123:3750–3759.
   PubMed Web of Science ®Google Scholar
• Zhu YM, Wu Z, Tan YP, et al. Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Two case reports. Medicine (Baltimore). 2016;95:e5676.
   PubMed Web of Science ®Google Scholar
• Geyer MB, Manjunath SH, Evans AG, et al. Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. Leuk Lymphoma. 2018;59:1717–1721.
   PubMed Web of Science ®Google Scholar
• Wang D, Shi R, Wang Q, et al. Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report. Onco Targets Ther. 2018;11:6327–6332.
   PubMed Web of Science ®Google Scholar
• Yang F, Yang X, Bao X, et al. Anti-CD19 chimeric antigen receptor T-cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation. Leuk Lymphoma. 2020;61:429–436.
   PubMed Web of Science ®Google Scholar
• Short NJ, Kantarjian H, Jabbour E, et al. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017;30:193–200.
   PubMed Web of Science ®Google Scholar
• Inoue C, Sobue S, Kawamoto Y, et al. Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I+Ph+ leukemia cells. Biochem Biophys Res Com. 2020;525:1974–1980.
   Web of Science ®Google Scholar
• Aldoss I, Forman SJ. How I treat adults with advanced acute lymphoblastic leukemia eligible for CD19-targeted immunotherapy. Blood. 2020;135:804–813.
   PubMed Web of Science ®Google Scholar
• Shah BD, Oluwole OO, Baer MR, et al. Outcomes of patients (pts) treated with prior blinatumomab (Blin) in ZUMA-3: a study of KTE-CD19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in adult pts with relapsed/refractory acute lymphoblastic leukemia (R/R ALL). J Clin Oncol. 2018;15(suppl.):7006.
   Web of Science ®Google Scholar
• Gardner R, Wu D, Cherian S, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–2410.
   PubMed Web of Science ®Google Scholar
• Jacoby E, Nguyen SM, Fountaine TJ, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320.
   PubMed Web of Science ®Google Scholar
• Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer. 2016;63:1113–1115.
   PubMed Web of Science ®Google Scholar
• Nagel I, Bartels M, Duell J, et al. Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood. 2017;130:2027–2031.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295.
   PubMed Web of Science ®Google Scholar
• Ereno-Orbea J, Sicard T, Cui H, et al. Molecular basis of human CD22 function and therapeutic targeting. Nat Commun. 2017;8:764.
   PubMed Web of Science ®Google Scholar